• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Flow Cytometry 2013: A Focus on Sales Growth - Product Image

Flow Cytometry 2013: A Focus on Sales Growth

  • ID: 2502553
  • February 2013
  • Region: Global
  • 167 Pages
  • BioPharm Reports (VennBio Ltd.)

This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the flow cytometry field.

Its findings include:

- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunities

This study was conducted through specialist groups of experienced flow cytometry end-users and its findings are therefore based on 'real world' market data.

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the flow cytometry field. Examples include:

- General Applications: Which general flow cytometry applications are the market leaders and what changes do end-users predict over the next three years. Which general flow cytometry techniques are growing and which are reducing?
- Clinical Applications: Which clinical flow cytometry applications are the market leaders and what changes do end-users predict over the next three years. Which clinical flow cytometry techniques are growing and which are reducing?
- Suppliers: Who are the major company READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

1 Introduction

2 Study Participants
Investigated: Participants' countries, regions, organisation types, departments and professional fields. Figures and/or tables are also presented.
2.1 This chapter
2.2 Countries
2.3 Regions
2.4 Organisation types
2.5 Departments
2.6 Fields
2.7 Discussion
Fields:
- Biotechnology
- Chemicals
- Clinical or Hospital
- Defense
- Diagnostics (Medical)
- Energy
- Environmental
- Food and Drink
- Forensics
- Geology
- Government
- Healthcare
- Natural Products
- Pharmaceuticals
- Research Institute
- Security
- University
- Other
Organisation types:
- University
- Research Institute
- Small or Medium Sized Company
- Large International Company
- Clinic or Hospital
- Government Organisation
- Veterinary Organisation
- Other

3 Purpose of Flow Cytometry
Investigated: Participants' purpose or reasons for using flow cytometry in their specified fields (see Fields, Chapter 2). The purposes or reasons for using flow cytometry, which may be unique to particular fields, were taken into account. Example: The purpose or reasons for using flow cytometry in the “Clinical or Hospital” field were clinical research, routine diagnostics, routine screening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology and other. Figures and/or tables are also presented.
3.1 This chapter
3.2 Purpose
3.3 Discussion

4 Main Activities
Investigated: The professional roles of study participants, namely as researchers or research managers, clinicians or physicians. Figures and/or tables are also presented.
4.1 This chapter
4.2 Researchers or Research Managers
4.3 Clinicians or Physicians
4.4 Discussion

5 Flow Cytometric Tests
Investigated: Participants' use of flow cytometry in one of three areas, namely i) the running of routine cytometric tests ii) the developing of new cytometric tests or iii) qualitative (cytometric) discovery. Figures and/or tables are also presented.
5.1 This chapter
5.2 Flow cytometric tests
5.3 Discussion

6 Therapeutic Area
Investigated: The therapeutic area(s) in which study participants work, relating to their use of flow cytometry. Figures and/or tables are also presented.
6.1 This chapter
6.2 Therapeutic Areas
6.3 Discussion
Therapeutic areas:
- Arthritis
- Autoimmune Diseases
- Bone Metabolism
- Cancer
- Cardiovascular
- Central Nervous System
- Dentistry
- Dermatology
- Endocrine
- Gastrointestinal
- Genito-urinary System
- Haematology
- Infections
- Inflammation
- Metabolic Disorders
- Musculoskeletal Disorders
- Nutrition
- Obstetrics and Gynaecology
- Ophthalmology
- Pain
- Psychiatry
- Respiratory
- Skin
- Other

7 Main Diseases
Investigated: The main disease areas in which study participants work, relating to their use of flow cytometry. Figures and/or tables are also presented.
7.1 This chapter
7.2 Disease areas
7.3 Discussion

8 Samples
Investigated: The sample types analysed by study participants, using flow cytometry. Figures and/or tables are also presented.
8.1 This chapter
8.2 Samples
8.3 Discussion
Sample types:
- Animal tissues
- Cerebrospinal fluid
- Bone Marrow
- Human tissues
- Microbiological materials
- Pathology samples
- Plant materials
- Lymph
- Saliva
- Urine
- Whole blood
- Other

9 General Applications
Investigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, in respect of 26 specified general applications, or others. Figures and/or tables are also presented.
9.1 This chapter
9.2 Current general applications
9.3 Anticipated future general applications
9.4 Discussion

10 Clinical Applications
Investigated: Participants current and anticipated future use (2012 – 2015) of flow cytometry, in respect of 19 specified clinical applications, or others. Figures and/or tables are also presented.
10.1 This chapter
10.2 Current clinical applications
10.3 Anticipated future clinical applications
10.4 Discussion

11 Main applications
Investigated: Participants main flow cytometry applications. Figures and/or tables are also presented.
11.1 This chapter
11.2 Main applications
11.3 Discussion

12 New Applications
Investigated: New flow cytometry applications that study participants anticipate they will be using in the next three years. Figures and/or tables are also presented.
12.1 This chapter
12.2 New applications
12.3 Discussion

13 Emerging Applications
Investigated: Emerging flow cytometry applications that study participants believe offer promise in their field. Figures and/or tables are also presented.
13.1 This chapter
13.2 Emerging applications
13.3 Discussion

14 Suppliers
Investigated: Participants current and an anticipated future (2012 – 2015) flow cytometry suppliers or vendors, in respect of 20 specified companies, or others. Figures and/or tables are also presented.
14.1 This chapter
14.2 Current suppliers
14.3 Future suppliers
14.4 Discussion

15 Main Flow Cytometer, Strengths and Weaknesses
Investigated: Participants main flow cytometer, in terms of their most frequently used system, together with their strengths and weaknesses. Figures and/or tables are also presented.
15.1 This chapter
15.2 Main flow cytometer
15.3 Discussion

16 Reagents and Assays
Investigated: Participants two main suppliers of reagents and assays for use in flow cytometry. Figures and/or tables are also presented.
16.1 This Chapter
16.2 Reagents and assays
16.3 Discussion

17 Sample Preparation
Investigated: Sample preparation methods used by participants, for flow cytometry studies. Figures and/or tables are also presented.
10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion

18 Software
Investigated: Participants use of data analysis (offline) software, for flow cytometry studies. Figures and/or tables are also presented.
18.1 This Chapter
18.2 Software
18.3 Discussion

19 Challenges
Investigated: The measurements or parameters that present the greatest technical challenge to study participants, relating to their use of flow cytometry. The parameter, sample type (matrix) and cytometer used were indicated, together with the main underlying reasons. Figures and/or tables are also presented.
19.1 This chapter
19.2 Parameters
19.3 Sample type (matrix)
19.4 Flow cytometer
19.5 Reasons
19.6 Discussion

20 Innovation
Investigated: Participants views on areas of required innovation (ranked on a scale of 1 to 10, where 1 is the least important and 10 is the most important), in respect of 10 specified areas, or others. Figures and/or tables are also presented.
20.1 This chapter
20.2 Innovation
20.3 Discussion

21 Disease Biomarkers
Investigated: Participants two main biomarkers investigated or measured using flow cytometry and their applications in terms of nine clinical utilities. Figures and/or tables are also presented.
21.1 This chapter
21.2 Biomarkers
21.3 Clinical utility
21.4 Discussion

22 Flow Cytometry Expenditure and Budgets
Investigated: Financial expenditure and budgets relating to the current and future use of flow cytometry, including end-users' current annual budgets across specified ranges (see Current Annual financial budgets), the average flow cytometry analysis costs/sample across specified ranges (see Flow Cytometry Costs per Sample), budget breakdown across nine specified areas (see Budget Breakdown Areas) and overall annual financial budget for flow cytometry (either increasing or decreasing in % terms), over the next three years (see Future Budget Changes). Figures and/or tables are also presented.
22.1 This chapter
22.2 Annual budgets
22.3 Costs per sample
22.4 Budget breakdown
22.5 Future budget
22.6 Discussion
Budget breakdown Areas
- Reagents and consumables
- System control (data handling) software
- Data analysis (offline) software
- Flow cytometer instruments
- Sample preparation and related instrumentation
- Ancillary systems/instrumentation
- General overheads
- Instrument servicing/repair
- Staff salaries
- Other

23 Consumables
Investigated: Participants two main consumables in terms of costs, that are directly associated with their use of flow cytometry. Figures and/or tables are also presented.
23.1 This Chapter
23.2 Consumables
23.3 Discussion

24 Quality Control
Investigated: Quality control systems or procedures adhered to in the use of flow cytometry. Figures and/or tables are also presented.
24.1 This chapter
24.2 Quality control
24.3 Discussion

Figures and Tables

Figure 2.1 Countries of individuals who participated in FC 2012
Figure 2.2 Global regions of individuals who participated in FC 2012.
Figure 2.3 Organisation types of individuals who participated in FC 2012
Figure 2.4 Fields of individuals who participated in FC 2012
Table 2.1 Countries of individuals who participated in FC 2012
Table 2.2 Global regions of individuals who participated in FC 2012
Table 2.3 Organisation types of individuals who participated in FC 2012
Figure 3.1 Top ten reasons for using FC in the biotechnology industry, indicated by individuals who participated in FC 2012
Figure 3.2 Top ten reasons for using FC in clinics or hospitals, indicated by individuals who participated in FC 2012
Figure 3.3 Top ten reasons for using FC in the energy industry, indicated by individuals who participated in FC 2012
Figure 3.4 Top ten reasons for using FC in diagnostics (medical), indicated by individuals who participated in FC 2012
Figure 3.5 Top ten reasons for using FC in the environmental industry, indicated by individuals who participated in FC 2012
Figure 3.6 Top ten reasons for using FC in the food and drink industry, indicated by individuals who participated in FC 2012
Figure 3.7 Top ten reasons for using FC in the Government organisations, indicated by individuals who participated in FC 2012
Figure 3.8 Top ten reasons for using FC in the healthcare industry, indicated by individuals who participated in FC 2012
Figure 3.9 Top ten reasons for using FC in the natural products industry, indicated by individuals who participated in FC 2012
Figure 3.10 Top ten reasons for using FC in the pharmaceutical industry, indicated by individuals who participated in FC 2012
Figure 3.11 Top ten reasons for using FC in research institutes, indicated by individuals who participated in FC 2012
Figure 3.12 Top ten reasons for using FC in universities, indicated by individuals who participated in FC 2012
Figure 4.1 Main activities of individuals using flow cytometry, indicated by individuals who participated in FC 2012
Figure 5.1 General flow cytometry tests carried out by individuals using flow cytometry, indicated by individuals who participated in FC 2012
Figure 6.1 Top ten therapeutic areas relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 6.1 Therapeutic areas relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 7.1 Top ten main diseases relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 7.1 Main diseases relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 8.1 Top ten sample types relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Table 8.1 Sample types relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 9.1 Top ten general applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 9.1 General applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 9.2 Top ten future (2012 - 2015) general applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 9.2 Future (2012 - 2015) general applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 10.1 Top ten clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 10.1 Clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 10.2 Top ten future (2012 - 2015) clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Table 10.2 Future (2012 - 2015) clinical applications of flow cytometry, indicated by individuals who participated in FC 2012
Figure 11.1 Top ten main applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 11.1 Main applications in flow cytometry, indicated by individuals who participated in FC 2012
Figure 12.1 Top ten new applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 12.1 New applications in flow cytometry, indicated by individuals who participated in FC 2012
Figure 13.1 Top ten emerging applications in flow cytometry, indicated by individuals who participated in FC 2012
Table 13.1 Emerging applications in flow cytometry, indicated by individuals who participated in FC 2012
Figure 14.1 Top ten suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Table 14.1 Suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Figure 14.1 Top ten future (2012 - 2015) suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Table 14.1 Future (2012 - 2015) suppliers of flow cytometry systems, indicated by individuals who participated in FC 2012
Figure 15.1 Top ten main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.1 Main flow cytometers, indicated by individuals who participated in FC 2012
Figure 15.2 Top ten strengths of main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.2 Strengths of main flow cytometers, indicated by individuals who participated in FC 2012
Figure 15.3 Top ten weaknesses of main flow cytometers, indicated by individuals who participated in FC 2012
Table 15.3 Weaknesses of main flow cytometers, indicated by individuals who participated in FC 2012
Figure 16.1 Top ten reagents and assays used in flow cytometry, indicated by individuals who participated in FC 2012
Table 16.1 Reagents and assays used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 17.1 Top ten sample preparation methods used in flow cytometry, indicated by individuals who participated in FC 2012
Table 17.1 Sample preparation methods used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 18.1 Top ten offline software used in flow cytometry, indicated by individuals who participated in FC 2012
Table 18.1 Offline software used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 19.1 Top ten technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.1 Technical challenges used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 19.2 Top ten sample types associated with technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.2 Sample types associated with challenges in flow cytometry, indicated by individuals who participated in FC 2012
Figure 19.3 Top ten flow cytometers associated with technical challenges in flow cytometry, indicated by individuals who participated in FC 2012
Table 19.3 Flow cytometers associated with challenges in flow cytometry, indicated by individuals who participated in FC 2012
Figure 20.1 Top five areas of required innovation in flow cytometry, indicated by individuals who participated in FC 2012
Table 20.1 Areas of required innovation in flow cytometry, indicated by individuals who participated in FC 2012
Figure 21.1 Top ten disease biomarkers studied using flow cytometry, indicated by individuals who participated in FC 2012
Table 21.1 Disease biomarkers studied using flow cytometry, indicated by individuals who participated in FC 2012
Figure 21.2 Top five disease biomarker clinical utilities in flow cytometry, indicated by individuals who participated in FC 2012
Table 21.2 Disease biomarkers clinical utilities in flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.1 Annual budgets for the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.2 Average costs/per sample using flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.3 Budget breakdown in nine key areas in flow cytometry, indicated by individuals who participated in FC 2012
Figure 22.4 Future budget changes (increases or decreases) relating to the use of flow cytometry, indicated by individuals who participated in FC 2012
Figure 23.1 Top ten consumables used in flow cytometry, indicated by individuals who participated in FC 2012
Table 23.2 Consumables used in flow cytometry, indicated by individuals who participated in FC 2012
Figure 24.1 Top ten quality control systems or procedures followed by flow cytometry users, indicated by individuals who participated in FC 2012
Table 24.1 Quality control systems or procedures followed by flow cytometry users, indicated by individuals who participated in FC 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos